When starting KEVEYIS, keep in touch with your patient on how they’re doing. Dosing can be modified at weekly intervals (or sooner in case of adverse reactions) based on individual response.
Check in with your patients weekly to see if a dose adjustment is needed.
The starting dose of KEVEYIS is 50 mg once or twice daily, which can be increased up to 200 mg daily or decreased for an individualized treatment approach.1 Please see Full Prescribing Information for monitoring information.
(pins and needles)
Our Patient Access Managers will check in with your patient regularly during the titration phase and beyond to help them evaluate how they’re feeling.
“Dealing with insurance companies is one of the biggest headaches PPP patients face. I get so much
satisfaction from being able to knock down those barriers to care for my patients and their providers.”
Valerie, Patient Access Manager
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Concomitant Use of Aspirin or Other Salicylates
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.
The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.
Please see Full Prescribing Information.
Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.
By submitting this form, I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals® Terms of Use and Privacy Statement. I understand I can unsubscribe by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email, phone, etc) to Xeris CareConnection™ Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607.
